| Literature DB >> 34941839 |
Farhan Ahmad Atif1, Saba Mehnaz1,2, Muhammad Fiaz Qamar3, Taleeha Roheen4, Muhammad Sohail Sajid2, Syed Ehtisham-Ul-Haque3, Muhammad Kashif1, Mourad Ben Said5,6.
Abstract
This review highlights the diagnostic methods used, the control strategies adopted, and the global epidemiological status of canine cyclic thrombocytopenia and granulocytic anaplasmosis at the animal-human interface. Canine anaplasmosis is an important worldwide disease, mainly caused by Anaplasma platys and A. phagocytophilum with zoonotic implications. A. platys chiefly infects platelets in canids, while A. phagocytophilum is the most common zoonotic pathogen infecting neutrophils of various vertebrate hosts. Diagnosis is based on the identification of clinical signs, the recognition of intracellular inclusions observed by microscopic observation of stained blood smear, and/or methods detecting antibodies or nucleic acids, although DNA sequencing is usually required to confirm the pathogenic strain. Serological cross-reactivity is the main problem in serodiagnosis. Prevalence varies from area to area depending on tick exposure. Tetracyclines are significant drugs for human and animal anaplasmosis. No universal vaccine is yet available that protects against diverse geographic strains. The control of canine anaplasmosis therefore relies on the detection of vectors/reservoirs, control of tick vectors, and prevention of iatrogenic/mechanical transmission. The control strategies for human anaplasmosis include reducing high-risk tick contact activities (such as gardening and hiking), careful blood transfusion, by passing immunosuppression, recognizing, and control of reservoirs/vectors.Entities:
Keywords: Anaplasma phagocytophilum; Anaplasma platys; canine anaplasmosis; control; diagnosis; epidemiology
Year: 2021 PMID: 34941839 PMCID: PMC8705095 DOI: 10.3390/vetsci8120312
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Classified and unclassified Anaplasma species infecting different cells, their vertebrate hosts, and their potential vectors.
| Infecting Cells | Vertebrate Hosts | Potential Vectors | References | |
|---|---|---|---|---|
|
| Platelets | Dogs and camels |
| [ |
|
| Granulocytes | Domestic and wild ruminants, horses, dogs, cats, rabbits, rodents, insectivores, wild swine, and humans | [ | |
|
| Erythrocytes | Domestic ruminants | [ | |
|
| Erythrocytes | Domestic and wild ruminants | [ | |
|
| Erythrocytes | Domestic and wild ruminants and humans |
| [ |
|
| Monocytes | Domestic and wild ruminants and small mammals | [ | |
|
| Erythrocytes | Domestic and wild ruminants and humans |
| [ |
|
| Platelets | Wild ruminants | Not known | [ |
| Not known | Camels | Not known | [ | |
| Not known | Not known |
| [ | |
| Not known | Domestic ruminants | Not known | [ | |
| Not known | Domestic ruminants | Not known | [ | |
| Not known | African penguins | Not known | [ | |
| Not known | Rodents | Not known | [ |
Detection of A. platys in domestic canid hosts from different countries *.
| Domestic Canid | Countries (Region) | Prevalences (%) | Methods (Target Genes) | References |
|---|---|---|---|---|
| Dog | Thailand | 13.9 | PCRa ( | [ |
| Thailand | 29.4 | PCRa ( | [ | |
| Thailand | 7.0 | PCRa ( | [ | |
| West Indies (Grenada) | 18.7 | PCRa ( | [ | |
| West Indies (Grenada) | 33.0 | PCRa ( | [ | |
| West Indies (Grenada) | 16.4 | RT-PCRd ( | [ | |
| West Indies (Trinidad) | 2.3 | PCRa ( | [ | |
| Pakistan | 11.34 | PCRa ( | [ | |
| Paraguay | 10.67 | PCRa ( | [ | |
| Colombia | 20.2 | RT-PCRd ( | [ | |
| Greece | Case report | Blood smear/ELISAc | [ | |
| Indonesia | 11.76 | PCRa ( | [ | |
| Cape Verde | 7.7 | PCRa ( | [ | |
| Italy | 70.5 | PCRa ( | [ | |
| Italy (Putignano) | 52.9 | RT-PCRc ( | [ | |
| Italy (Teramo Kennel) | 33.0 | PCRa ( | [ | |
| Croatia | Case report | RT-PCRd ( | [ | |
| Australia | 51.3 | RT-PCRd ( | [ | |
| Australia | 23.7 | ELISAc | [ | |
| Australia | 32.0 | PCRa ( | [ | |
| Australia | 3.8 | Blood smear/ELISAc/PCRa | [ | |
| Romania | Case report | PCRa ( | [ | |
| Dominican Republic | 11 | RT-PCRd ( | [ | |
| Nicaragua | 13 | RT-PCRd( | [ | |
| Caribbean | 10.3 | ELISAc | [ | |
| Canada | 1.8 | ELISAc | [ | |
| USA (South) | 2.0 | ELISAc | [ | |
| USA (Mid Atlantic) | 1.1 | ELISAc | [ | |
| USA (Northeast) | 1.5 | ELISAc | [ | |
| USA (Midwest) | 0.6 | ELISAc | [ | |
| USA (West) | 1.0 | ELISAc | [ | |
| Mexico | 31.0 | PCRa ( | [ | |
| Brazil | 7.19 | PCRa ( | [ | |
| Turkey | 0.5 | RLBd | [ | |
| Costa Rica | 1 | PCRa ( | [ | |
| Brazil | 16.96 | nPCRf ( | [ | |
| Brazil | 19.4 | PCRa ( | [ | |
| Brazil | 14.07 | nPCRf ( | [ | |
| Colombia | 53.0 | PCRa ( | [ | |
| Palestine | 53.0 | PCRa ( | [ | |
| China | 62.1 | RT-LAMPg/nPCRf ( | [ | |
| Caribbean | 18.7 | PCRa ( | [ | |
| Argentina | 37.5 | PCRa ( | [ | |
| Costa Rica | 6.25 | nPCRf ( | [ | |
| Myanmar | 0.25 | PCRa ( | [ | |
| Malawi | 2.4 | PCRa ( | [ | |
| Galápagos | 6.9 | PCRa ( | [ | |
| Saudi Arabia | 57.1 | RT-PCRc ( | [ | |
| Greek islands | 18.0 | PCRa ( | [ | |
| Malta | 22.7 | PCRa ( | [ | |
| Haiti | 6.3 | PCRa ( | [ | |
| Cambodia | 32.0 | NGSi based metabarcoding | [ | |
| Uganda | 18.9 | RT-PCRd ( | [ | |
| Albania | 3.3 | PCRa ( | [ | |
| Nigeria | 6.6 | RT-PCRd ( | [ | |
| Qatar | 1.6 | PCRa ( | [ | |
| Texas | 0.17 | RT-PCRd ( | [ | |
| India | 22.6 | PCRa ( | [ | |
| Japan | 32.0 | PCRa ( | [ |
a Polymerase chain reaction; b multiplex high-resolution melting analysis; c enzyme-linked immunosorbent assay; d real-time polymerase chain reaction; e reverse line blot hybridization; f nested polymerization chain reaction; g real-time loop-mediated isothermal amplification; h indirect fluorescent antibody test; i next-generation sequencing based on metabarcoding. * Detection of A. platys from 1991 up to date.
Detection of A. phagocytophilum from the tissue or blood of domestic canids hosts *.
| Domestic Canid | Countries (Regions) | Prevalences (%) | Methods(Target Genes) | References |
|---|---|---|---|---|
| Dog | Iraq | 55.6 | Blood smear | [ |
| Iran | 2.0 | PCR a ( | [ | |
| Mexico | 27 | PCRa (16S rRNA) | [ | |
| USA (California) | 7.6 | RT-PCRb ( | [ | |
| Brazil | 7.1 | RT-PCRb ( | [ | |
| USA (South) | 2.1 | ELISAc | [ | |
| USA (Mid-Atlantic) | 5.4 | ELISAc | [ | |
| USA (Northeast) | 13 | ELISAc | [ | |
| USA (Midwest) | 1.9 | ELISAc | [ | |
| USA (West) | 2.0 | ELISAc | [ | |
| Canada | 1.1 | ELISAc | [ | |
| Caribbean | 3.4 | ELISAc | [ | |
| Sweden | 17.0 | IFATd | [ | |
| Colombia | 1.1 | PCRa (16S rRNA) | [ | |
| Costa Rica | 0.3 | PCRa (16SrRNA, | [ | |
| India | 0.4 | PCRa (16S/18S rRNA) | [ | |
| Turkey | 4.0 | nPCRe (16S rRNA) | [ |
a Polymerase chain reaction; b real-time polymerase chain reaction; c enzyme-linked immunosorbent assay; d indirect fluorescent antibody test; e nested polymerization chain reaction. * Detection of A. phagocytophilum from 1998 up to date.
Figure 1Blue color Anaplasma phagocytophilum in the cytoplasm of neutrophils in dog blood; Wright’s stain, 1000× (source: https://eclinpath.com; accessed on 11 August 2021; Cornell University College of Veterinary Medicine).
Figure 2Blue–purple inclusions of Anaplasma platys in dog blood with thrombocytopenia; Wright’s stain 1000× (source: https://eclinpath.com; accessed on 11 August 2021; Cornell University College of Veterinary Medicine).
Figure 3Human A. phagocytophilum infection, indicating morulae in infected neutrophils [142].
Summary of the clinical findings, diagnosis, and control of canine cyclic thrombocytopenia, and canine and human granulocytic anaplasmosis.
| Disease | Clinical Findings | Diagnosis | Treatment | Control |
|---|---|---|---|---|
| Canine cyclic thrombocytopenia | Dogs usually remain asymptomatic; however, fever, lethargy, anorexia, weight loss, anemia, icterus, petechiae, nasal discharge, lymphadenopathy, and lymphadenomegaly may beobserved [ | Stained blood smear, thrombocytopenia, serology, and PCR/DNA sequencing [ | Doxycycline @5–10 mg kg−1 q12–24 h for 8–10 days orenrofloxacin @ 5mg kg−1, q12 h for 14–21 days [ | Tick elimination, collar, pour-on or spot-on acaricidal products for |
| Canine granulocytic | Non-specific signs, fever, anemia, anorexia, dullness, and thrombocytopenia [ | Morulae in stained blood smear, thrombocytopenia, leucopenia, elevated liver enzymes, serology, andPCR/DNA sequencing [ | Doxycycline 5mg/kg bid for 28 days [ | Vector control, habitat modification, rearing tick-resistant breeds, and chemotherapy [ |
| Human granulocyticanaplasmosis | Fever, headache, myalgias, and chills [ | Morulae in stained blood smear, thrombocytopenia, leucopenia, elevated liver enzymes, serology/IFA, and PCR/DNA sequencing [ | Doxycycline @ 100mg, orally, twice dailyfor 10–14 days or | Humans: Minimizing high-risk tick exposure activities |